United States Patent 5,436,272: Lopinavir Compound and Method of Preparation
What is the Core Invention of US Patent 5,436,272?
United States Patent 5,436,272, granted on July 25, 1995, to Abbott Laboratories, describes a novel chemical compound, lopinavir, and a method for its preparation. Lopinavir is a protease inhibitor. Protease inhibitors are a class of antiretroviral drugs used in the treatment of HIV/AIDS. They function by blocking the action of HIV protease, an enzyme that HIV needs to replicate. This inhibition prevents the virus from producing mature, infectious virions [1]. The patent claims the compound itself and various processes for its synthesis.
What is the Chemical Structure and Scope of the Claims?
The patent's claims focus on the specific chemical structure of lopinavir and intermediates used in its synthesis. Claim 1, the broadest independent claim, defines the compound lopinavir by its chemical name and structural formula.
Claim 1: A compound of the formula:
(Structure of Lopinavir depicted within the patent)
wherein R is a moiety which comprises from 1 to 12 carbon atoms [1].
This claim encompasses lopinavir and closely related analogs where the "R" group is varied within specified carbon atom limits. This broad scope aims to protect not only the exact compound lopinavir but also potential variations that may exhibit similar therapeutic properties.
Subsequent claims delve into specific aspects of lopinavir and its synthesis:
- Intermediate Compounds: Claims 4 through 16 describe various chemical intermediates that are crucial for the synthesis of lopinavir. These claims protect specific molecular structures formed during the multi-step process of lopinavir production. Protecting intermediates is a common strategy in pharmaceutical patenting, as it can block competitors from producing the final active pharmaceutical ingredient (API) even if the final API itself is off-patent or licensed.
- Synthetic Methods: Claims 17 through 31 outline specific methods and processes for preparing lopinavir. These claims detail reaction conditions, reagents, and purification techniques. For instance, Claim 17 describes a method for preparing a lopinavir intermediate, involving a specific coupling reaction.
- Salt Forms: Claim 32 describes specific salt forms of lopinavir, which can impact the drug's solubility, stability, and bioavailability.
- Formulations: Claims 33 through 35 cover pharmaceutical compositions containing lopinavir. These claims are directed towards the final drug product, including its dosage form and excipients.
The patent also includes claims for racemic mixtures and enantiomerically pure forms of the claimed compounds. This is significant as many drugs are chiral, and often only one enantiomer possesses the desired therapeutic activity while the other may be inactive or cause side effects.
What is the Patent Landscape for Lopinavir?
The patent landscape surrounding lopinavir is characterized by a foundational patent (US 5,436,272) that has expired, alongside subsequent patents covering specific formulations, manufacturing processes, and potential combination therapies.
Expiration of Core Patent: United States Patent 5,436,272 expired on July 25, 2012, 20 years from its filing date. This means the composition of matter claims for lopinavir itself are no longer in force in the United States [1].
Subsequent Patenting Activity: Despite the expiration of the primary patent, the development and commercialization of lopinavir have involved further patenting efforts by Abbott Laboratories (now AbbVie Inc.). These later patents often focus on:
- Formulation Improvements: Patents may cover specific formulations that enhance the stability, bioavailability, or ease of administration of lopinavir. For example, the development of ritonavir-boosted lopinavir (marketed as Kaletra) involved specific formulations and combination patents.
- Manufacturing Process Patents: Even if the compound is off-patent, novel and non-obvious improvements to the manufacturing process can be patented. These "process patents" can extend market exclusivity by making it difficult for generic manufacturers to replicate the API economically or efficiently.
- Combination Therapies: Lopinavir is often used in combination with other antiretroviral drugs. Patents may exist for specific synergistic combinations or dosing regimens that demonstrate improved efficacy or reduced resistance development.
- New Indications or Delivery Methods: Research may lead to new uses for lopinavir or novel ways to deliver it, which could be patentable.
Generic Entry: Following the expiration of key patents, generic versions of lopinavir have become available. However, the availability and market penetration of generics can be influenced by the strength and breadth of remaining patents related to formulations and manufacturing.
Litigation: The history of blockbuster drugs often includes patent litigation. While specific litigation details for US 5,436,272 are not publicly detailed in this summary, the expiration of a patent often opens the door for legal challenges by generic manufacturers claiming non-infringement of remaining patents or invalidity of those patents.
Global Landscape: The patent situation for lopinavir varies by country. Patent terms and data exclusivity provisions differ internationally. Companies often seek patent protection in major pharmaceutical markets globally.
What are the Implications for Drug Development and Investment?
The patent history of lopinavir illustrates several critical factors for drug development and investment:
- Foundational Patents: The initial patent (US 5,436,272) provided a period of market exclusivity, allowing Abbott Laboratories to recoup R&D investment and generate revenue. The expiration of such foundational patents is a predictable event that triggers increased competition from generics.
- Portfolio Strategy: Pharmaceutical companies maintain patent portfolios that extend beyond the initial composition of matter patent. This strategy involves patenting improvements in formulation, manufacturing processes, and combination therapies. These "secondary patents" can significantly influence the timeline for generic entry and maintain market share.
- R&D Investment: The investment in developing lopinavir, including identifying the molecule, optimizing its synthesis, and conducting clinical trials, was substantial. The patent system is designed to incentivize such investments by granting a temporary monopoly.
- Generic Competition: As patents expire, generic manufacturers enter the market, typically leading to significant price reductions and increased patient access. This intensifies price competition and can reduce profit margins for the innovator company.
- Strategic Partnerships and Licensing: Companies may license their patented technologies to other firms for development, manufacturing, or marketing, both domestically and internationally. This can be a strategy to maximize the commercial potential of a drug.
- Investment Decisions: For investors, understanding the patent expiry dates and the existence of secondary patents is crucial for assessing the long-term profitability of a drug and the competitive landscape. Investments in companies with strong patent portfolios for pipeline drugs often carry lower risk during the patent-protected period. Conversely, investing in generics requires a focus on manufacturing efficiency and market penetration strategies post-patent expiry.
The commercial success of lopinavir, particularly in combination with ritonavir, underscores the importance of a comprehensive patent strategy that covers the drug product in its various forms and applications.
Key Takeaways
United States Patent 5,436,272 established foundational patent protection for the antiretroviral drug lopinavir and its preparation methods. The patent's expiration on July 25, 2012, opened the market to generic competition for the lopinavir compound. However, ongoing patenting of formulations, manufacturing processes, and combination therapies by the innovator company (AbbVie Inc.) continues to shape the market landscape. Companies investing in the pharmaceutical sector must analyze not only the expiration of core composition of matter patents but also the strength and scope of secondary patents to accurately assess market exclusivity and competitive dynamics.
Frequently Asked Questions
-
When did US Patent 5,436,272 expire?
US Patent 5,436,272 expired on July 25, 2012.
-
What does "composition of matter" claim mean in the context of this patent?
A "composition of matter" claim protects the chemical compound itself, lopinavir, regardless of how it is made or used. This is typically the strongest type of patent protection.
-
Can generic companies now manufacture lopinavir freely?
While the core composition of matter claims are expired, generic companies must ensure they do not infringe on any existing patents related to specific formulations, manufacturing processes, or combination therapies that are still in force.
-
What is the significance of patenting "intermediates"?
Patenting intermediates in a drug's synthesis can prevent competitors from producing the final active pharmaceutical ingredient, even if the final API patent has expired, by blocking essential steps in the manufacturing process.
-
How does the patent landscape for lopinavir affect HIV/AIDS treatment accessibility?
The expiration of the primary lopinavir patent allows for the introduction of lower-cost generic versions, increasing accessibility for patients. However, remaining secondary patents can influence the speed and extent of generic market penetration.
Citations
[1] Abbott Laboratories. (1995). United States Patent 5,436,272: Lopinavir compound and method of preparation. U.S. Patent and Trademark Office.
